Researchers have developed a new test to predict which patients with newly diagnosed breast cancer have excellent probability of response and survival following chemotherapy. Using an algorithm combining genomic information from the biopsy of a patient’s tumor, the test identified those for whom standard therapy had high probability of success, as well as those who might benefit from participating in a clinical trial.
W. Fraser Symmans, M.D.
“The research builds on a decade of collaborative work in developing a clinically meaningful chemotherapy predictor,” says W. Fraser Symmans, M.D., professor in MD Anderson’s Department of Pathology.
“If validated in future studies, it could guide therapy for about 80% of newly diagnosed women with invasive breast cancer who are candidates for chemotherapy,”
Reported in the May 11, 2011, issue of the Journal of the American Medical Association.